Form 4: Processa Pharmaceuticals Executive Patrick Lin Reports Changes in Beneficial Ownership

Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units.

Summary

• On April 5, 2024, Patrick Lin acquired 1,675 shares of common stock through the distribution of vested restricted shares and disposed of 539 shares to cover tax obligations at a price of $2.79 per share.
• On July 10, 2024, Lin acquired 644 shares of common stock through the distribution of vested restricted shares and disposed of 271 shares to cover tax obligations at a price of $1.71 per share.
• Lin also holds multiple tranches of Restricted Stock Units (RSUs) that convert to common stock, vesting at various dates including January 1, 2025, and January 1, 2027, some of which are contingent upon achieving certain performance goals.
• Following these transactions, Lin directly owns 29,059 shares of common stock and holds 24,914 Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, so the sentiment is neutral. It reflects insider transactions, which don't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders can monitor insider transactions for insights into management's perspective on the company's stock.

Key Dates

Keywords

Form 4, Beneficial Ownership, Restricted Stock Units, Common Stock, Processa Pharmaceuticals, Insider Trading